For the cumulative third quarter of fiscal 2025, revenue was JPY 1,533.5 billion (YoY +12.1%), core operating income was JPY 249.2 billion (YoY +8.8%), and net income attributable to owners of parent was JPY 217.4 billion (YoY +4.2%), reflecting profit growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4568-20260130-03.pdf","jir_short_summary":"For the cumulative third quarter of fiscal 2025, revenue was JPY 1,533.5 billion (YoY +12.1%), core operating income was JPY 249.2 billion (YoY +8.8%), and net income attributable to owners of parent was JPY 217.4 billion (YoY +4.2%), reflecting profit growth.","jir_summary":"### Overview of Business Performance\nFor the cumulative third quarter of fiscal 2025, revenue was JPY 1,533.5 billion, a 12.1% increase year-over-year, and core operating income was JPY 249.2 billion, up 8.8% year-over-year. Key products Enhertu\u00ae and Datopotamab Deruxtecan\u00ae showed steady growth, contributing to the revenue increase. Operating income declined year-over-year due to the impact of one-time income and expenses, but net income increased by 4.2%. The exchange rates were USD\/JPY 148.75 and EUR\/JPY 171.84.\n\n### Segment Revenue Changes and Product Trends\nThe revenue increase drivers include an 88.5 billion yen increase in Enhertu\u00ae and a 22.5 billion yen increase in Datopotamab Deruxtecan\u00ae within the Oncology Business Unit, along with revenue growth in Datopotamab Deruxtecan\u00ae, Belsomra, Lixiana, and Talicia by the Japan Business Unit and others. Conversely, declines were seen in Inavir and Daiichi Sankyo Espha. The global product Enhertu\u00ae maintained the number one new patient share in major countries and steadily expanded its new patient share in first-line treatment of HER2-positive breast cancer in the U.S. Datopotamab Deruxtecan\u00ae sales approximately 1.5 times increased from the previous quarter-end, achieving sales growth exceeding expectations in the U.S. and Japan.","jir_financial_highlights":"Revenue: JPY 1,533.5 billion (YoY +12.1%)\nCore Operating Income: JPY 249.2 billion (YoY +8.8%)\nOperating Income: JPY 233.8 billion (YoY -5.9%)\nNet Income Attributable to Owners of Parent: JPY 217.4 billion (YoY +4.2%)","jir_category":"","jir_hashtags":"#DaiichiSankyo, #FinancialResultsBriefing, #JapaneseStocks","jir_key_figures":"Revenue: JPY 1,533.5 billion (YoY +12.1%)\nCore Operating Income: JPY 249.2 billion (YoY +8.8%)\nNet Income Attributable to Owners of Parent: JPY 217.4 billion (YoY +4.2%)","jir_meta_title":"Daiichi Sankyo Fiscal Year 2025 Q3 Financial Results Revenue JPY 1,533.5 Billion and Core Operating Income JPY 249.2 Billion with Profit Growth","jir_meta_description":"Daiichi Sankyo\u2019s fiscal year 2025 Q3 financial results briefing. Revenue was JPY 1,533.5 billion (YoY +12.1%), core operating income was JPY 249.2 billion (+8.8%), and net income was JPY 217.4 billion (+4.2%) reflecting profit growth. Key products Enhertu\u00ae and Datopotamab Deruxtecan\u00ae performed strongly.","jir_og_title":"Daiichi Sankyo Reports Fiscal Year 2025 Q3 Financial Results with Revenue and Profit Growth","jir_og_description":"Daiichi Sankyo\u2019s fiscal year 2025 Q3 financial results briefing. Achieved profit growth with revenue of JPY 1,533.5 billion, core operating income of JPY 249.2 billion, and net income of JPY 217.4 billion.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal 2024\\\",\\\"Fiscal 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (billion JPY)\\\",\\\"data\\\":[13676,15335],\\\"backgroundColor\\\":\\\"#4A90E2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"core_operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Core Operating Income Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal 2024\\\",\\\"Fiscal 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Income (billion JPY)\\\",\\\"data\\\":[2290,2492],\\\"backgroundColor\\\":\\\"#50E3C2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal 2024\\\",\\\"Fiscal 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (billion JPY)\\\",\\\"data\\\":[2483,2338],\\\"backgroundColor\\\":\\\"#F5A623\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Cumulative Q3)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Fiscal 2024\\\",\\\"Fiscal 2025\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income (billion JPY)\\\",\\\"data\\\":[2086,2174],\\\"backgroundColor\\\":\\\"#D0021B\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"product_sales_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Main Product Sales Increase\/Decrease (billion JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Enhertu\\\",\\\"Datopotamab Deruxtecan\\\",\\\"Belsomra\\\",\\\"Lixiana\\\",\\\"Talicia\\\",\\\"Inavir\\\",\\\"Daiichi Sankyo Espha\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Increase\\\",\\\"data\\\":[885,225,92,89,74,0,0],\\\"backgroundColor\\\":\\\"#4CAF50\\\"},{\\\"label\\\":\\\"Decrease\\\",\\\"data\\\":[0,0,0,0,0,122,112],\\\"backgroundColor\\\":\\\"#F44336\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22165","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n